Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

NCT02358356 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.

NCT NCT02358356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02358356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
October 31, 2021
Enrollment
75 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

midgut neuroendocrine tumours, pancreatic neuroendocrine tumours